Key result
Specific antidotes reverse DOAC-related bleeding, with idarucizumab and andexanet alfa approved and ciraparantag in development.
Why the study?
There is limited information regarding reversal approaches for bleeding risks associated with inappropriate use of DOACs, and specific antidotes are being developed and approved.
This review summarizes the current landscape of specific reversal agents for direct oral anticoagulants to manage life-threatening bleeding and urgent surgical needs.
Answers are grounded in this paper and cite their sources.
Antidote access may aid urgent DOAC bleeding management; leaves open optimal strategies pending higher-level evidence.
Currently, the use of Direct Oral Anticoagulants (DOACs) has become more common place since this group of drugs was developed to overcome the limitations of warfarin. However, inappropriate use of DOACs may increase the risk of bleeding. There is a need for an antidote which reverses this risk of bleeding from use or overuse of DOACs as well as to prevent bleeding associated with DOACs in patients undergoing emergency or elective surgery. Management guidelines are based on the level of urgency, severity and/or place of bleeding. Unfortunately, there is limited information regarding this reversal approach. Currently, specific antidotes for DOACs are being developed and approved for clinical use. The first approved specific antidote, idarucizumab, is indicated to reverse dabigatran’s effects in patients with a life-threatening haemorrhage or in need of urgent surgery. However, idarucizumab does not antagonize effects of other DOACs. In 2018, Andexanet alfa was approved by the USFDA for the reversal of apixaban’s and rivaroxaban’s effects. Lastly, ciraparantag, the universal antidote which reverses effects of both factor Xa inhibitors and factor IIa inhibitors, is under investigation.
No takes yet. Share an insight, caveat, or question.
Vipa Thammatinno (2021) conducted a review in Bleeding associated with Direct Oral Anticoagulants (DOACs). Specific antidotes for DOACs (idarucizumab, andexanet alfa, ciraparantag) was evaluated. Specific antidotes for direct oral anticoagulants, such as idarucizumab and andexanet alfa, have been developed and approved to reverse bleeding risks, with ciraparantag under investigation.
Synapse has enriched 10 related papers. Consider them for comparative context: